Question:
What code and modifier should be used to report an injection of the biosimilar drug infliximab?
Answer:
Q5102 (effective April 5, 2016) can be reported with either the existing modifier ZB (Pfizer/Hospira, effective April 1, 2016) or new modifier ZC (Merck/Samsung Bioepis, effective July 1, 2017).